(Albany, United States) As per DelveInsight’s assessment, globally, the Uveitis pipeline constitutes 15+ key companies continuously working towards developing 15+ Uveitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Uveitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Uveitis clinical trials studies, Uveitis NDA approvals (if any), and product development activities comprising the technology, Uveitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Uveitis pipeline treatment landscape of the report, click here @ Uveitis Pipeline Outlook
Key Takeaways from the Uveitis Pipeline Report
- DelveInsight’s Uveitis Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
- The leading Uveitis Companies working in the market include Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others
- Promising Uveitis Pipeline Therapies in the various stages of development include Izokibep, Adalimumab, Predinisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Izokibep, Prednisone/Prednisolone, Baricitinib, Sarilumab, Methotrexate, and others.
- On June 2023, ACELYRIN Inc announced a study of phase 2 clinical trials for Izokibep. Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
- On April 2023, Bio-Thera Solutions announced a study of phase 4 clinical trials for QLETLI. This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
- On February 2023, ACELYRIN Inc announced a study of phase 2 clinical trials for Izokibep. This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).
Uveitis Overview
Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. Uveitis is swelling of the middle layer of the eye, which is called the uvea.
To explore more information on the latest breakthroughs in the Uveitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight
Uveitis Emerging Drugs Profile
- Barcitinib: Eli Lilly and Company
- EYS606: Eyevensys
Uveitis Pipeline Therapeutics Assessment
There are approx. 15+ Uveitis companies which are developing the therapies for Uveitis. The Uveitis companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.
Request a sample and discover the recent advances in Uveitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight
Uveitis Drugs and Companies
- Izokibep: AcelyRin Inc
- Adalimumab: AbbVie
- Prednisone: Abbott
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg: EyePoint Pharmaceuticals Inc
- QLETLI: Bio-Thera Solutions
Uveitis Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Uveitis Therapeutics Market include-
Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others
Dive deep into rich insights for drugs for Uveitis Pipeline, click here for Uveitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight
Scope of the Uveitis Pipeline Report
- Coverage- Global
- Uveitis Companies- Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others
- Uveitis Pipeline Therapies- Izokibep, Adalimumab, Predinisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Izokibep, Prednisone/Prednisolone, Baricitinib, Sarilumab, Methotrexate, and others.
- Uveitis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Uveitis Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Uveitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Baricitinib: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- EYS606: Eyevensys
- Drug profiles in the detailed report…..
- Early stage products (Phase I/II)
- TRS01: Tarius Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Uveitis Key Companies
- Uveitis Key Products
- Uveitis- Unmet Needs
- Uveitis- Market Drivers and Barriers
- Uveitis- Future Perspectives and Conclusion
- Uveitis Analyst Views
- Uveitis Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services